Comparative Pharmacology
Head-to-head clinical analysis: CHLORZOXAZONE versus ROBAXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORZOXAZONE versus ROBAXIN.
CHLORZOXAZONE vs ROBAXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Centrally acting muscle relaxant; depresses polysynaptic reflexes at spinal cord and supraspinal levels, possibly via glycine receptor agonism and GABAergic modulation.
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
1500 mg orally 4 times daily, or 750 mg orally every 4 hours as needed. Maximum 6 g/day. For IV use: 1 g (10 mL) as a single intravenous injection or infusion.
None Documented
None Documented
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Clinical Note
moderateChlorzoxazone + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fluticasone propionate."
Clinical Note
moderateChlorzoxazone + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Chlorzoxazone."
Clinical Note
moderateChlorzoxazone + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Chlorzoxazone."
Clinical Note
moderateChlorzoxazone + Sulfisoxazole
1-2 hours in adults; clinically, multiple daily dosing required to maintain effect.
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
Renal excretion of metabolites accounts for 99% of elimination; <1% excreted as unchanged drug in urine.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The metabolism of Sulfisoxazole can be decreased when combined with Chlorzoxazone."